30 July 2019 in Medizinische Klinik - Intensivmedizin und Notfallmedizin
14 September 2020 in Catheterization and Cardiovascular Interventions
Objectives: This study aimed to identify the incidence and potential risk factors for delirium after myocardial infarction (MI).Background: Delirium is a common complication on intensive care units. Data on incidence and especially on predictors of delirium in patients after acute MI are rare.Methods: In this retrospective study, all patients hospitalized for MI treated with coronary angiography in an university hospital in 2018 were included and analyzed. Onset of delirium within the first 5 days after MI was attributed to the MI and was defined by a Nursing Delirium screening scale (NuDesc) ≥2. This score is taken as part of daily care in every patient on intensive care unit three times a day by especially trained nurses.Results: A total of 624 patients with MI (age 68.5 ± 13.2 years, ST‐elevation MI 41.6%, hospital mortality 3.2%) were included in the study. Delirium was detected in 10.9% of all patients. In the subgroup of patients with a stay on the intensive care unit (ICU) for more than 24 hr (n = 229), delirium was detected in 29.7%. Hospital and ICU stay were significantly longer in patients with delirium (p < .001). Delirium was an independent predictor of prolonged ICU‐stay. Independent predictors of delirium were age, dementia, alcohol abuse, cardiac arrest, hypotension, and leucocytosis. Infarct size or presentation with ST‐elevation were not associated with incidence of delirium.Conclusion: Development of delirium is frequent after acute MI and prolongs hospitalization. Incidence of delirium is associated with clinical instability, preexisting comorbidity, and age rather than MI type or size.
12 July 2019 in Clinical Research in Cardiology
DSDawid Leander Staudacher
Aim Cardiac arrest is the most serious complication in acute coronary syndromes. Glycoprotein IIb/IIIa inhibitors (GPI) are used in selected acute coronary syndrome patients. If the use of GPI leads to an increase in bleeding events and influences survival in patients after cardiac arrest is unknown. Methods We report retrospective data of a single center registry of patients after successful intra- and out-of-hospital cardiac arrest between 2002 and 2013. Inclusion criteria were survival for at least 6 h and successful percutaneous coronary intervention (PCI) within the first 24 h. Patients treated with other fibrinolytic agents or being supported by an extracorporeal life support system were excluded from the analysis. Results 310 patients were included in our study. 204 received GPI (GPI+), 106 did not (GPI−). Patients in the GPI+ group were significantly younger (62.8 vs. 68.0 years, p < 0.001) and had larger myocardial infarction sizes (maximum creatine kinase 3407 vs. 1450 U/l, p < 0.001). CPR duration, SOFA score and first lactate did not differ between the groups. Any bleeding occurred significantly more often in the GPI+ group (83.3% vs. 67.0%, p = 0.001). Decline of hemoglobin within the first 24 h was higher in the GPI+ group (−1.59 ± 1.71 mg/dl vs. −0.88 ± 1.95 mg/dl, p = 0.004), number of transfused packed red blood cells in the first 4 days, however, were similar (1.18 ± 0.40 vs. 0.90 ± 0.41 packs, p = 0.378). Survival at ICU discharge was significantly higher in the GPI+ group (77.5% vs. 63.2%, p = 0.008). The use of GPI was an independent predictor of hospital survival (OR 3.07, CI 1.31−7.20, p = 0.010). The positive effect for GPI persisted after nearest neighbor propensity score matching including 144 patients (OR 3.27, 95% CI 1.48−7.21, p = 0.003). Conclusion After cardiac arrest, bleeding incidence was significantly higher in patients treated with GPI. Incidence of bleedings requiring transfusion, however, was similar. In this retrospective analysis, the use of GPI was an independent predictor of hospital survival. We suggest that GPI may not be withheld from cardiac arrest survivors due to potential risk of bleeding. Graphic abstract
31 October 2025 in Infection
Objectives: After the COVID-19 pandemic an increase in Group A streptococcal (GAS) infections was reported mostly for children in several countries worldwide. However, data on infections in adults remain limited. Therefore, we focus on the pre- and post-pandemic incidence of GAS infections in adults, the need for intensive care treatment and the microbiological sampling patterns. Methods: We performed a retrospective cohort study of hospitalized adult patients from 2012 to 2024, based on a positive GAS detection in their routine microbiological sampling. We compared the post-pandemic phase after lifting the isolation measures in April 2022 to the pandemic and pre-pandemic phase. Additionally, we analysed positive rapid assessment tests in children, indicative of the prevalence of GAS tonsillitis in this population. Results: In the post-pandemic months, we observed a significant increase in overall hospitalized adult patients (IRR 2.94) and ICU patients (IRR 2.5) with GAS infections. The rise can be attributed to an increase in both invasive and non-invasive GAS detections. Conclusions: The increase in GAS infections is not only relevant in paediatric patients, but also has significant relevance in adult patients. Physicians need to be aware of this increase. The data of 2024 show a sustained increase and an incidence that has not returned to pre-pandemic levels.
12 April 2021 in Neurocritical Care
A correction to this paper has been published: https://doi.org/10.1007/s12028-021-01225-0
3 June 2020 in DMW - Deutsche Medizinische Wochenschrift
Was ist neu?: Diagnostik von Coronavirus-Infektionen Die Diagnostik der Wahl bleibt der Nachweis mittels PCR im Nasopharyngealsekret. Die PCR-Positivität bei Nasen-Rachen-Abstrichen hält oft länger als 10 Tage an und wird anschließend auch bei klinischer Gesundung noch einige Tage intermittierend beobachtet. Die Erregerzahl ist dann jedoch meistens niedrig, und Viruskulturen in dieser Zeit sind in der Regel negativ, es besteht also meist keine Infektiosität mehr. Krankheitsbild Die Hauptkomplikation der SARS-CoV-2-Infektion ist die Pneumonie mit Entwicklung eines akuten Atemnotsyndroms (ARDS). Asymptomatische und oligosymptomatische Verläufe mit Virussauscheidung sind nicht selten, bei Kindern sind sie möglicherweise häufiger als bei Erwachsenen. Die Virusausscheidung bei symptomlosen Menschen und in der präsymptomatischen Phase einer Infektion ist für Übertragungen relevant. Therapieoptionen und Impfung Eine effektive antivirale Therapie ist bisher nicht etabliert. Steroide zur antientzündlichen Therapie werden nicht empfohlen. Ein Impfstoff wird frühestens Mitte bis Ende 2021 erwartet. Epidemiologie Die bisherigen Angaben zur Sterblichkeit der SARS-CoV-2-Infektion sind widersprüchlich; die Sterblichkeit ist sicher niedriger als bei SARS und MERS, vermutlich jedoch höher als bei den meisten saisonalen Grippewellen der letzten Jahre. Eine Vorbereitung aller Akteure im Gesundheitswesen auf eine längerfristige Belastung durch stationär Behandlungspflichtige und Komplikationen und Schaffung entsprechender Kapazitäten ist sehr wichtig. Niederschwelliges diagnostisches Testen und rasches Aufdecken von Infektionsketten bleiben wesentlich zur besseren Kontrolle der Pandemie. Eine effektive Vakzine ist dringlich.